<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019534</url>
  </required_header>
  <id_info>
    <org_study_id>ChiECRCT20210210</org_study_id>
    <nct_id>NCT05019534</nct_id>
  </id_info>
  <brief_title>Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I Study on Tolerance and Safety of Vemurafenib Film-coated Tablets, Cetuximab Solution for Infusion and Camrelizumab Protocol(VCC) in the After Line Therapy of BRAF V600E Mutation/MSS Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is&#xD;
      the most common type, which is an important biomarker for predicting the prognosis and&#xD;
      precise treatment efficacy of metastatic colorectal cancer (mCRC). The prognosis of&#xD;
      metastatic colorectal cancer with BRAF V600E mutation is very poor, with OS of about 6-9&#xD;
      months. Previous studies have shown that single anti-BRAF inhibitor are ineffective, while&#xD;
      multi-target inhibitions of Ras-Raf -MEK pathway is a possible effective strategy for BRAF&#xD;
      V600E-mutant mCRC. Currently, the proven effective regimens include the VIC regimen&#xD;
      (Vemurafenib + cetuximab + Irinotecan) and BEACON regimen (Encorafenib+ cetuximab +/-&#xD;
      Binimetinib) from the SWOGS1406 study. Furthermore, BRAF inhibitor +MEK inhibitor combined&#xD;
      with PD-1 monoclonal antibody has been shown to be an effective strategy in BRAF V600E-mutant&#xD;
      malignant melanoma, which promote the study of the regimens for the treatment of BRAF&#xD;
      V600E-mutant mCRC. Increasing basic and clinical studies have shown that cetuximab has ADCC&#xD;
      effect, induces immunogenic cell death, promotes immune cell infiltration and other&#xD;
      immunomodulatory effects, and has a synergistic effect with PD-1 monoclonal antibody in&#xD;
      colorectal cancer. Based on those theories, we conducted the phase I study to explore the&#xD;
      safety and preliminary efficacy of the regimen of Vemurafenib (BRAFi) plus cetuximab (EGFRi)&#xD;
      combined with PD-1 monoclonal antibody in BRAF V600E-mutant /MSS type mCRC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the recommended Phase 2 dose(RP2D) or the maximum tolerated dose(MTD)</measure>
    <time_frame>Subjects will be treated and observed for dose-limiting toxicity(DLT) through the end of the first cycle (Days 1-28)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Object Response Rate (ORR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Rate of patients with partial or complete response according to modified RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Progression free survival (Medium, Kaplan-Meier-estimation, ITT- population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>the proportion of patients who had a best response rating of complete response, partial response, or stable disease according to modified RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 3 year</time_frame>
    <description>Overall survival (Kaplan-Meier-estimation, ITT- population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular markers</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Evaluation of molecular predictive markers for response and toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>BRAF V600E-mutated /MSS Metastatic Colorectal Cancer</condition>
  <condition>Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody</condition>
  <arm_group>
    <arm_group_label>Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab and Camrelizumab in the fixed dose Vemurafenib have two dose groups: 960mg qd or 960mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib Oral Tablet [Zelboraf]</intervention_name>
    <description>Vemurafenib 960mg qd or 960mg bid (2 cohorts)</description>
    <arm_group_label>Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab Injection [Erbitux]</intervention_name>
    <description>Cetuximab 500mg/m2 Q2W</description>
    <arm_group_label>Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab 200mg Q2W</description>
    <arm_group_label>Vemurafenib, Cetuximab Combined With Camrelizumab (VCC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years of age&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2&#xD;
&#xD;
          3. Participants must have histologically or cytologically confirmed diagnosis of&#xD;
             adenocarcinoma of the colon or rectum, with clinical confirmation of unresectable&#xD;
             and/or metastatic disease that is measurable according to Response Evaluation Criteria&#xD;
             in Solid Tumors (RECIST 1.1) criteria&#xD;
&#xD;
          4. Presence of BRAF V600E in tumor tissue determined by local assay at any time prior to&#xD;
             screening and confirmed by central laboratory. And confirmation of MSS or pMMR status&#xD;
             from immunohistochemistry or PCR or NGS;&#xD;
&#xD;
          5. Prior treatment with at least one systemic treatment (chemotherapy or target therapy)&#xD;
             for mCRC, and prior treatment did not include cetuximab&#xD;
&#xD;
          6. Adequate organ and marrow function:&#xD;
&#xD;
               -  ①Hemoglobin (Hb) ≥ 90 g/L；Platelets (PLT) ≥ 75 x 10^9/L；Neutrophil ≥1.5 x 10^9/L&#xD;
&#xD;
               -  ②Total bilirubin ≤ 1.5 x upper limit of normal (ULN)；Aspartate aminotransferase&#xD;
                  (AST) ≤3 x ULN ；Alanine aminotransferase (ALT) ≤3 x ULN&#xD;
&#xD;
               -  ③Serum creatinine ≤ 1.5 x ULN, or calculated creatinine clearance (determined as&#xD;
                  per Cockcroft-Gault) ≥ 50 mL/min at screening&#xD;
&#xD;
               -  ④INR, APTT, and PT≤ 1.5 x ULN&#xD;
&#xD;
               -  ⑤Serum albumin≥ 28 g/L&#xD;
&#xD;
               -  ⑥ECG showed no evident abnormality&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or contraindication to any component of cetuximab or PD-1&#xD;
             monoclonal antibody or macromolecular protein reagent.&#xD;
&#xD;
          2. A history of other malignancies with a disease-free survival of less than 5 years,&#xD;
             with the following exceptions: adequately treated basal or squamous cell skin cancer,&#xD;
             carcinoma in-situ of the cervix, and gastrointestinal tumors treated curatively with&#xD;
             endoscopic mucosectomy;&#xD;
&#xD;
          3. Any active autoimmune disease or a history of autoimmune disease&#xD;
&#xD;
          4. Use of immunosuppressive medications or glucocorticoid therapy ≤2 weeks prior to entry&#xD;
&#xD;
          5. Uncontrolled active infection requiring antibiotics&#xD;
&#xD;
          6. Known history of HIV infection or active hepatitis&#xD;
&#xD;
          7. Severe complications, including any of the following:&#xD;
&#xD;
               -  ①Massive gastrointestinal bleeding, perforation, or gastrointestinal obstruction&#xD;
&#xD;
               -  ②Symptomatic heart disease&#xD;
&#xD;
               -  ③Uncontrolled diabetes and hypertension&#xD;
&#xD;
               -  ④Uncontrolled diarrhea&#xD;
&#xD;
          8. Women who are pregnant or lactating and people who do not agree to avoid pregnancy&#xD;
&#xD;
          9. Patients with serious psychiatric that may interfere treatment.&#xD;
&#xD;
         10. Other conditions which are inappropriate to participate in the study confirmed by&#xD;
             investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meng Qiu</last_name>
    <phone>+862885423203</phone>
    <email>qiumeng33@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weibing Leng, Ph.D</last_name>
    <phone>+8618980601776</phone>
    <email>s103470@stu.scu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sichuan University West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibing Leng, Ph.D</last_name>
      <phone>+8618980601776</phone>
      <email>s103470@stu.scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Meng Qiu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

